Filing Details

Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001193125-19-016025)

NAME OF REPORTING PERSON OR

  I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

  Aisling Capital IV, LP

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐ (b) ☒

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

Accession Number:: 0001193125-19-016025
Form Type:: 13G Filing
Publication Date:: 2019-01-24 17:21:02

Filed By:: Aisling Capital Iv, Lp
Company:: Viracta Therapeutics Inc. (NASDAQ:VIRX)
Filing Date:: 2019-01-24
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Aisling Capital IV	7,600,000	0	7,600,000	0	7,600,000	12.6%
Aisling Capital Partners IV	7,600,000	0	7,600,000	0	7,600,000	12.6%
Aisling Capital Partners IV	7,600,000	0	7,600,000	0	7,600,000	12.6%
Steve Elms	0	7,600,000	0	7,600,000	7,600,000	12.6%
Andrew Schiff	0	7,600,000	0	7,600,000	7,600,000	12.6%

Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Sunesis Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

867328502

(CUSIP Number)

January 23, 2019

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed.

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 867328502		SCHEDULE 13G		Page 2 of 11


CUSIP No. 867328502		SCHEDULE 13G		Page 3 of 11


CUSIP No. 867328502		SCHEDULE 13G		Page 4 of 11


CUSIP No. 867328502		SCHEDULE 13G		Page 5 of 11


CUSIP No. 867328502		SCHEDULE 13G		Page 6 of 11


CUSIP No. 867328502		SCHEDULE 13G		Page 7 of 11

ITEM 1.

(a)

Name of Issuer:

Sunesis Pharmaceuticals, Inc. (the Issuer)

(b)

Address of Issuers Principal Executive Offices:

395 Oyster Point Boulevard, Suite 400

South San Francisco, CA 94080

ITEM 2.

(a)

Name of Person Filing:

This Schedule 13G (this Statement) is being filed by the following persons (collectively, the Reporting Persons):

(i)

Aisling Capital IV, LP, a Delaware limited partnership (Aisling);

(ii)

Aisling Capital Partners IV, LP, a Delaware limited partnership (Aisling Partners), a general partner of Aisling;

(iii)

Aisling Capital Partners IV LLC, a Delaware limited liability company (Aisling Partners GP), a general partner of Aisling Partners;

(iv)

Mr. Steve Elms, a managing member of Aisling Partners GP;

(v)

Mr. Andrew Schiff, a managing member of Aisling Partners GP.

(b)

Address of Principal Business Office, or if None, Residence:

The address of the principal business offices of each of the Reporting Persons is 888 Seventh Avenue, 12th Floor, New York, New York 10106.

(c)

Citizenship:

(i)

Aisling - a Delaware limited partnership

(ii)

Aisling Partners - a Delaware limited partnership

(iii)

Aisling Partners GP - a Delaware limited liability company

(iv)

Mr. Elms - United States

(v)

Mr. Schiff - United States

(d)

Title of Class of Securities:

Common Stock, par value $0.0001 per share (the Common Stock).

(e)

CUSIP Number:

867328502

ITEM 3.

IF THIS STATEMENT IS FILED PURSUANT TO §240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

(a)

☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)

(b)

☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c)

(c)

☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c)

(d)

☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)

(e)

☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E)

(f)

☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);


CUSIP No. 867328502		SCHEDULE 13G		Page 8 of 11

(g)

☐ A Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)

☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)

(i)

☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)

(j)

☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

(k)

☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

ITEM 4.

OWNERSHIP

(a)

Amount beneficially owned:

Each of the Reporting Persons may be deemed to beneficially own an aggregate of 7,600,000 shares of Common Stock.

(b)

Percent of class:

Based on the calculations made in accordance with Rule 13d-3(d), each of the Reporting Persons may be deemed to beneficially own approximately 12.6% of the outstanding Common Stock as of the date hereof.

All percentages of ownership of the Common Stock by Reporting Persons presented in this Statement assume an aggregate of 60,421,509 shares of Common Stock issued and outstanding, as reported in the Issuers Prospectus Supplement filed with the Securities and Exchange Commission on January 17, 2019.

(c)

Number of shares as to which such person has:

(i), (iii)

Sole power to vote or to direct the vote/Sole power to dispose of or to direct the disposition of:

As of the date hereof, each of Aisling, Aisling Partners and Aisling Partners GP may be deemed to have sole power to direct the voting and disposition of the 7,600,000 shares of Common Stock beneficially owned by Aisling.

(ii), (iv)

Shared power to vote or to direct the vote/Shared power to dispose of or to direct the disposition of:

By virtue of the relationships between and among the Reporting Persons as described in Item 2, each of Messrs. Elms and Schiff may be deemed to share the power to direct the voting and the disposition of the 7,600,000 shares of Common Stock beneficially owned by Aisling as of the date hereof.

ITEM 5.

OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

Not Applicable.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.


CUSIP No. 867328502		SCHEDULE 13G		Page 9 of 11

ITEM 6.

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

The partners of Aisling have the right to participate in the receipt of dividends from, or proceeds from the sale of, the Common Stock held for the account of Aisling in accordance with their ownership interests in Aisling.

ITEM 7.

IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

Not Applicable.

ITEM 8.

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

Not Applicable.

ITEM 9.

NOTICE OF DISSOLUTION OF GROUP

Not Applicable.

ITEM 10.

CERTIFICATIONS.

By signing below I hereby certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


CUSIP No. 867328502		SCHEDULE 13G		Page 10 of 11

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: January 24, 2019


AISLING CAPITAL IV, LP

By: Aisling Capital Partners IV, LP, As its General Partner

By: Aisling Capital Partners IV LLC, As its General Partner

By:		/s/ Andrew Schiff
		Name: Andrew Schiff Title: Managing Member

AISLING CAPITAL PARTNERS IV, LP

By: Aisling Capital Partners IV LLC, As its General Partner

By:		/s/ Andrew Schiff
		Name: Andrew Schiff Title: Managing Member

AISLING CAPITAL PARTNERS IV LLC

By:		/s/ Andrew Schiff
		Name: Andrew Schiff Title: Managing Member

STEVE ELMS

By:		/s/ Steve Elms

ANDREW SCHIFF

By:		/s/ Andrew Schiff


CUSIP No. 867328502		SCHEDULE 13G		Page 11 of 11

EXHIBIT INDEX


Exhibit 1.		Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (previously filed).